Angion Biomedica Corp. (ANGN): history, ownership, mission, how it works & makes money

From its founding in 1998 developing small-molecule therapeutics to a transformative deal that reshaped its future, Angion Biomedica's journey-culminating in a public debut that raised $117 million via an IPO of 5,750,000 shares at $16.00 apiece and a reverse merger completed on June 1, 2023-now continues under the Elicio Therapeutics name as a clinical-stage immunotherapy company leveraging proprietary Amphiphile (AMP) technology and a lead program, ELI-002, in Phase 2 against mutant KRAS tumors; the post-merger ownership split left roughly 65.5% of the combined company with pre-merger Elicio holders and about 34.5% with former Angion holders, while operational realities underscore the high stakes-Elicio reported a $51.9 million net loss for 2024, a cumulative deficit of $194.1 million and only $17.6 million in cash as of December 31, 2024-set against a business model that monetizes through equity financings, strategic partnerships, and eventual commercialization of AMP-based, off-the-shelf cancer vaccines, and a quality commitment evidenced by a 97% FDA compliance audit score that speaks to its manufacturing rigor and regulatory focus.

Angion Biomedica Corp. (ANGN): Intro

• Founded: 1998 - focus on small molecules for acute organ injury and fibrosis.
• IPO: February 2021 - raised $117 million via 5,750,000 shares at $16.00 per share.
• Merger: January 2023 - definitive merger agreement with Elicio Therapeutics, Inc.
• Completion & rebrand: June 1, 2023 - merged company adopted the Elicio Therapeutics, Inc. name.
• Leadership post‑merger: Elicio executive team assumed management; Robert Connelly named CEO; Jay Venkatesan retained a board seat.
• Status (as of December 2025): operates as a clinical‑stage company advancing immunotherapies for cancer under the Elicio name.

• Original mission: develop therapies to prevent or treat acute organ injury and pathologic fibrosis by modulating reparative biology.
• Post‑merger mission: leverage combined expertise to advance next‑generation immunotherapies for cancer, accelerating clinical development and translational science.

• Research & development: primary expense and value driver-preclinical and clinical programs funded by equity raises and partnerships.
• Capital raises: public offering (Feb 2021 IPO) provided major non‑dilutive runway; other financings and collaborations typical for clinical‑stage firms.
• Business development: licensing, collaborations, or asset sales could monetize programs before product approval.
• Future revenue paths (post‑merger): product sales upon regulatory approval, out‑licensing, milestone and royalty streams, and strategic partnerships in oncology.

• Post‑merger executive leadership transitioned to Elicio's management team; Robert Connelly became CEO.
• Board continuity included former Angion director Jay Venkatesan continuing on the combined board.

Angion Biomedica Corp. (ANGN): History

• NASDAQ listing (pre-merger): ANGN
• Primary clinical focus: renal repair and fibrosis-related indications (clinical-stage assets)
• Commercial status: pre-revenue / development-stage

• Acquirer: Elicio Therapeutics, Inc. (NASDAQ: ELTX)
• Structure: reverse merger - Elicio merged into Angion; combined company adopted the Elicio name and ticker
• Post-merger ownership: pre-merger Elicio equity holders ≈ 65.5% of outstanding shares; pre-merger Angion equity holders ≈ 34.5%
• Combined company ticker: ELTX on the NASDAQ Global Market

• Mission: advance regenerative/reparative biologics to address unmet medical needs in organ injury and fibrosis
• How it works: discover and develop biologic or small-molecule candidates through preclinical and clinical stages, then seek partnerships, licensing or commercialization pathways
• How it makes money: no material product revenue pre-commercialization - value generation primarily via clinical-stage milestones, licensing deals, strategic partnerships, equity raises and eventual product commercialization or acquisition

Angion Biomedica Corp. (ANGN) Ownership Structure

• Mission and values: Angion emphasizes innovation in renal and cardiorenal therapeutics, patient-centric development, and adherence to regulatory quality standards.
• Patient engagement: the company engages patient groups and advocacy networks to inform trial design and patient-facing materials.
• Quality and compliance: maintains robust manufacturing and quality controls aligned with FDA expectations.

• Major institutional holders typically include large asset managers and biotech-focused funds (e.g., Vanguard, BlackRock, and specialized healthcare funds), which together drive a significant portion of trading volume and governance votes.
• Insider stakes (executive team and board) help align management incentives with long‑term value creation, while institutional ownership brings governance discipline and research coverage.

• Clinical development and licensing: primary near-term value derives from clinical-stage assets and potential milestone or license agreements with partners.
• Grants and collaborations: research collaborations and government or foundation grants supplement R&D funding.
• Equity financing: common for pre-revenue biotechs to raise capital via public or private equity offerings to fund trials.

Angion Biomedica Corp. (ANGN): Mission and Values

• AMP conjugation binds vaccine peptides/adjuvants to endogenous albumin, exploiting albumin's natural trafficking to lymphatics and concentrating payloads in draining lymph nodes.
• Lymph node localization amplifies antigen presentation by dendritic cells and promotes robust CD8+ and CD4+ T‑cell priming relative to conventional systemic delivery.
• Localized delivery reduces systemic exposure and inflammation while enhancing magnitude and durability of T‑cell responses-critical for effective cancer immunotherapy.

• KRAS mutations are among the most common oncogenic drivers: present in >90% of pancreatic ductal adenocarcinomas, ~40% of colorectal cancers, and ~20-30% of lung adenocarcinomas-making KRAS a high‑value shared neoantigen target for off‑the‑shelf vaccines.
• BRAF V600 and other oncogenic BRAF variants represent a well‑characterized driver in subsets of melanoma, colorectal and other cancers; targeting mutant BRAF peptides can engage T cells against tumor‑specific neoantigens.
• TP53 is the most frequently mutated tumor suppressor across cancers; mutant‑p53 neoantigens offer broad applicability if immunogenic epitopes can be presented effectively.

• Drug development value creation: advancing vaccine candidates through clinical milestones (Phase 1 → Phase 2 → registrational studies) to raise enterprise value and attract partnerships or licensing deals.
• Biotech financings and collaborations: monetizing programs via out‑licensing, co‑development agreements, or strategic partnerships with larger pharma to obtain upfronts, milestones, and royalties.
• Potential commercial sales: if off‑the‑shelf neoantigen vaccines demonstrate efficacy, recurring product revenue from broader patient populations (shared driver mutations across cancer types) rather than bespoke personalized vaccine pricing models.

• Operations and R&D have been financed through equity issuances (common stock), private placements, and capital raised in the merger transaction that brought Elicio's AMP platform into Angion's public corporate structure.
• Such financings are used to support clinical trials (e.g., ongoing Phase 2 activity for ELI‑002), preclinical development of ELI‑007 and ELI‑008, manufacturing scale‑up for off‑the‑shelf product formats, and general corporate overhead.

• Off‑the‑shelf design removes per‑patient manufacturing lead time and high costs associated with personalized neoantigen vaccines, enabling faster treatment initiation and scalable commercial supply chains.
• Targeting shared oncogenic driver mutations (KRAS, BRAF, TP53) enables broader addressable patient populations compared to individualized neoantigen approaches.
• Lymph node‑targeted AMP formulation enhances the quality and magnitude of T‑cell responses, which can improve clinical efficacy and potentially synergize with checkpoint inhibitors or other immunotherapies.

Angion Biomedica Corp. (ANGN): How It Works

• Core focus: development of therapeutic candidates targeting organ protection, repair and regeneration.
• R&D model: in-house discovery and translational development combined with outsourced CRO services for clinical trials.
• Value creation pathway: preclinical proof-of-concept → Phase 1/2 safety and dose-finding → pivotal trials → regulatory approval or partnership/licensing for commercialization.

• Equity financing: issuance of common stock and private placements to raise operating capital.
• Mergers and corporate transactions: strategic mergers and acquisitions to consolidate assets and pipeline (including the merger referenced with Elicio in recent corporate activity history).
• Limited operating revenue: as a clinical-stage biotech, near-term revenue is constrained and dependent on future commercialization or partner-funded programs.
• Funding strategy: ongoing equity offerings and partnership deals to support R&D and clinical programs.

• High clinical risk: financial performance is highly sensitive to clinical trial outcomes and regulatory approvals.
• Cash runway pressure: modest cash balances relative to R&D burn necessitate additional capital raises or partner funding.
• Potential upside: successful clinical data or partnering deals can materially increase company value and create revenue streams via milestones, royalties or product sales.

• Public equity: listed shares (ticker: ANGN) trade on public markets, with institutional and retail holders.
• Board and management: governance focused on clinical progression, capital management and strategic partnering to advance pipeline.

Angion Biomedica Corp. (ANGN): How It Makes Money

• Core revenue model (potential): licensing deals, milestone and royalty income from partnerships, and eventual product sales upon regulatory approval.
• Primary near-term value drivers: clinical trial readouts, strategic collaborations, and non-dilutive financing (e.g., grants, milestone-based partner payments).

• Competitive landscape: Faces established biotech and large pharma rivals in renal and fibrosis indications; differentiation rests on mechanism of action and clinical differentiation versus standard of care.
• Scientific differentiation: Proprietary approaches aimed at tissue repair and modulation of regenerative pathways seek to address unmet needs in organ injury-if clinical efficacy is demonstrated, potential to capture specialized hospital and specialty nephrology markets.
• Clinical risk: As a clinical-stage firm, Angion's valuation and future revenue hinge on successful trial outcomes and regulatory approvals; negative readouts would materially constrain commercialization prospects.
• Financial constraints: The company operates with an accumulated deficit typical of R&D biotech and limited cash runway absent additional financing or partnership revenue; securing additional capital or partnership milestones is critical to continue development programs.
• Outlook dependencies: Advancement of the pipeline through pivotal studies, in-license or out-license deals, and commercialization strategy execution will determine medium-to-long-term revenue generation.